Standout Papers
- Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients (2008)
- Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies (2009)
- Principles and use of anti-CTLA4 antibody in human cancer immunotherapy (2006)
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates (2010)
- Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients (2003)
- Checkpoint Blockade in Cancer Immunotherapy (2006)
- Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma (2013)
Citation Impact
Citing Papers
CTLA-4 blockade increases IFNγ-producing CD4 + ICOS hi cells to shift the ratio of effector to regulatory T cells in cancer patients
2008
Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial
2010 StandoutNobel
Intratumoral Immune Cell Infiltrates, FoxP3, and Indoleamine 2,3-Dioxygenase in Patients with Melanoma Undergoing CTLA4 Blockade
2008
Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy
2014 Standout
Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts
2010 StandoutNobel
The ICOS/ICOSL Pathway Is Required for Optimal Antitumor Responses Mediated by Anti–CTLA-4 Therapy
2011
Tumor Vaccines Expressing Flt3 Ligand Synergize with CTLA-4 Blockade to Reject Preimplanted Tumors
2009 StandoutNobel
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
2009 Standout
Naive tumor-specific CD4+ T cells differentiated in vivo eradicate established melanoma
2010
PD-1 Blockade Enhances T-cell Migration to Tumors by Elevating IFN-γ Inducible Chemokines
2012
Controlled Local Delivery of CTLA-4 Blocking Antibody Induces CD8+ T-Cell–Dependent Tumor Eradication and Decreases Risk of Toxic Side Effects
2013
A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma
2009
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
2003 StandoutNobel
A Phase I Pharmacokinetic and Biological Correlative Study of IMP321, a Novel MHC Class II Agonist, in Patients with Advanced Renal Cell Carcinoma
2009
Spatially selective depletion of tumor-associated regulatory T cells with near-infrared photoimmunotherapy
2016
Potent Induction of Tumor Immunity by Combining Tumor Cryoablation with Anti–CTLA-4 Therapy
2011 StandoutNobel
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma
2013 StandoutNobel
Combined Targeting of Costimulatory (OX40) and Coinhibitory (CTLA-4) Pathways Elicits Potent Effector T Cells Capable of Driving Robust Antitumor Immunity
2013
Checkpoint Blockade Immunotherapy Relies on T-bet but Not Eomes to Induce Effector Function in Tumor-Infiltrating CD8+ T Cells
2014
CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion
2008 StandoutNobel
Trans-Endocytosis of CD80 and CD86: A Molecular Basis for the Cell-Extrinsic Function of CTLA-4
2011 Science
Two Distinct Mechanisms of Augmented Antitumor Activity by Modulation of Immunostimulatory/Inhibitory Signals
2010 StandoutNobel
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
2012 StandoutScienceNobel
Induction of tumoricidal function in CD4+ T cells is associated with concomitant memory and terminally differentiated phenotype
2012
Mouse models of acute and chronic hepacivirus infection
2017 StandoutScienceNobel
VISTA Regulates the Development of Protective Antitumor Immunity
2014
Deletion of CTLA-4 on regulatory T cells during adulthood leads to resistance to autoimmunity
2015
Trastuzumab emtansine (T-DM1) renders HER2 + breast cancer highly susceptible to CTLA-4/PD-1 blockade
2015
Anti-TIM3 Antibody Promotes T Cell IFN-γ–Mediated Antitumor Immunity and Suppresses Established Tumors
2011
Distinctive Features of the Differentiated Phenotype and Infiltration of Tumor-Reactive Lymphocytes in Clear Cell Renal Cell Carcinoma
2012
Enterocolitis in Patients With Cancer After Antibody Blockade of Cytotoxic T-Lymphocyte–Associated Antigen 4
2006
Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target
2004
Increased Frequency of ICOS+ CD4 T Cells as a Pharmacodynamic Biomarker for Anti-CTLA-4 Therapy
2013 StandoutNobel
CTLA-4 Controls Regulatory T Cell Peripheral Homeostasis and Is Required for Suppression of Pancreatic Islet Autoimmunity
2009
PD-1 Is a Regulator of NY-ESO-1-Specific CD8+ T Cell Expansion in Melanoma Patients
2009
Active Immunotherapy Combined With Blockade of a Coinhibitory Pathway Achieves Regression of Large Tumor Masses in Cancer-prone Mice
2011
A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma
2011
PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
2017 StandoutNature
Hallmarks of Cancer: The Next Generation
2011 Standout
First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity
2010
The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigens
1987 StandoutNature
Elements of cancer immunity and the cancer–immune set point
2017 StandoutNature
Extended Co-Expression of Inhibitory Receptors by Human CD8 T-Cells Depending on Differentiation, Antigen-Specificity and Anatomical Localization
2012
Oncology Meets Immunology: The Cancer-Immunity Cycle
2013 Standout
Recent Advances Using Anti-CTLA-4 for the Treatment of Melanoma
2009
Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab
2015
Correction of the cystic fibrosis defect in vitro by retrovirus-mediated gene transfer
1990 Standout
Clinical Development of the Anti–CTLA-4 Antibody Tremelimumab
2010
Combination cancer immunotherapy and new immunomodulatory targets
2015
Combining immunotherapy and targeted therapies in cancer treatment
2012
Treg and CTLA-4: Two intertwining pathways to immune tolerance
2013
Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment
2014
CTLA-4 blockade synergizes with cryoablation to mediate tumor rejection
2012 StandoutNobel
Structure of the human class I histocompatibility antigen, HLA-A2
1987 StandoutNature
Enhancement of tumor immunotherapy by deletion of the A2A adenosine receptor
2011
Regulatory T Cells in Cancer
2010
Agonist Anti-GITR Monoclonal Antibody Induces Melanoma Tumor Immunity in Mice by Altering Regulatory T Cell Stability and Intra-Tumor Accumulation
2010
Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial
2012
A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma
2010
Intrinsic and extrinsic control of peripheral T‐cell tolerance by costimulatory molecules of the CD28/ B7 family
2011
Qa-1 restricted recognition of foreign antigen by a γδ T-cell hybridoma
1989 Nature
CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells
2006
Interdependent IL-7 and IFN-γ signalling in T-cell controls tumour eradication by combined α-CTLA-4+α-PD-1 therapy
2016 StandoutNobel
PD-1/PD-L1 pathway and T-cell exhaustion in chronic hepatitis virus infection
2010
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
2012
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
2015 StandoutNobel
Translational Research Working Group Developmental Pathway for Immune Response Modifiers
2008
Regulatory T cells, tumour immunity and immunotherapy
2006 Standout
Ipilimumab (Anti-CTLA4 Antibody) Causes Regression of Metastatic Renal Cell Cancer Associated With Enteritis and Hypophysitis
2007
Inhibitory B7-family molecules in the tumour microenvironment
2008
Dendritic cells in cancer immunotherapy
2010
The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses
2011
Role of Dendritic Cell Phenotype, Determinant Spreading, and Negative Costimulatory Blockade in Dendritic Cell-Based Melanoma Immunotherapy
2004
Tumor-infiltrating lymphocytes: apparently good for melanoma patients. But why?
2011
CTLA-4 blockade increases antigen-specific CD8+ T cells in prevaccinated patients with melanoma: three cases
2011 StandoutNobel
Improved Endpoints for Cancer Immunotherapy Trials
2010
Regulatory T Cells Control Antigen-Specific Expansion of Tfh Cell Number and Humoral Immune Responses via the Coreceptor CTLA-4
2014 StandoutNobel
Regulatory T cells in cancer immunotherapy
2016 StandoutNobel
Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase
2007
Combination CTLA-4 Blockade and 4-1BB Activation Enhances Tumor Rejection by Increasing T-Cell Infiltration, Proliferation, and Cytokine Production
2011 StandoutNobel
Co-inhibitory molecules of the B7–CD28 family in the control of T-cell immunity
2004
CTLA-4 suppresses the pathogenicity of self antigen–specific T cells by cell-intrinsic and cell-extrinsic mechanisms
2009
Restoring function in exhausted CD8 T cells during chronic viral infection
2005 StandoutNatureNobel
Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line
1990 Standout
Cancer immunotherapy comes of age
2011 StandoutNature
The blockade of immune checkpoints in cancer immunotherapy
2012 Standout
Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells
1988 StandoutNature
Combination immunotherapy with α-CTLA-4 and α-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma
2015
LAG-3 in Cancer Immunotherapy
2010
FOXP3+ regulatory T cells in the human immune system
2010 StandoutNobel
Therapeutic vaccines for cancer: an overview of clinical trials
2014
Regulatory T cells in cancer immunotherapy
2014 StandoutNobel
Designing Vaccines Based on Biology of Human Dendritic Cell Subsets
2010
Distinct antigen receptor repertoires of two classes of murine epithelium-associated T cells
1989 StandoutNatureNobel
Tumor cell expression of programmed cell death‐1 ligand 1 is a prognostic factor for malignant melanoma
2010 StandoutNobel
HLA-DQβ gene contributes to susceptibility and resistance to insulin-dependent diabetes mellitus
1987 StandoutNature
Eomesodermin is required for antitumor immunity mediated by 4-1BB-agonist immunotherapy
2014
Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade
2017 StandoutNobel
Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure)
2016
Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy
2007
Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience
2015
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
2015 Standout
A TALE nuclease architecture for efficient genome editing
2010 Standout
Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor
1994 Standout
A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application
2013 StandoutNobel
Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication
2011 StandoutNobel
Fluorescent indicators for Ca2+based on green fluorescent proteins and calmodulin
1997 StandoutNatureNobel
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
2009
Limited diversity of γδ antigen receptor genes of thy-1+ dendritic epidermal cells
1988 StandoutNobel
Human FOXP3+ Regulatory T Cell Heterogeneity and Function in Autoimmunity and Cancer
2019 StandoutNobel
An immune-active tumor microenvironment favors clinical response to ipilimumab
2011
Potentiating Endogenous Antitumor Immunity to Prostate Cancer through Combination Immunotherapy with CTLA4 Blockade and GM-CSF
2009
Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
2012 Standout
Molecular Pathways: Next-Generation Immunotherapy—Inhibiting Programmed Death-Ligand 1 and Programmed Death-1
2012
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
2015 Standout
Recent Developments in Cancer Vaccines
2011
A program for prediction of protein secondary structure from nucleotide sequence data: application to histocompatibility antigens
1984
Isotypic and allotypic variation of human class II histocompatibility antigen α-chain genes
1984 Nature
What Is the Role of Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade in Patients with Metastatic Melanoma?
2009
Molecular characterization of three HLA class II molecules on DR4 and DRw9 haplotypes: Serologic and structural relationships at the polypeptides level
1986
Complete primary structures of the E beta chain and gene of the mouse major histocompatibility complex.
1983 StandoutNobel
Increased Frequency of N-Region Insertion in a Murine Pre-B-Cell Line Infected with a Terminal Deoxynucleotidyl Transferase Retroviral Expression Vector
1987 Nobel
Efficient Presentation of Phagocytosed Cellular Fragments on the Major Histocompatibility Complex Class II Products of Dendritic Cells
1998 StandoutNobel
Coinhibitory Pathways in Immunotherapy for Cancer
2016
Complete sequence of an HLA-dR beta chain deduced from a cDNA clone and identification of multiple non-allelic DR beta chain genes.
1983
Sequence relationships between putative T-cell receptor polypeptides and immunoglobulins
1984 Nature
Mapping of the class II region of the human major histocompatibility complex by pulsed-field gel electrophoresis
1986 Nature
HLA-DR2 subtypes form an additional supertypic family of DR beta alleles.
1987
Integrated NY-ESO-1 antibody and CD8+T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab
2011 StandoutNobel
Methylation of the HLA-DR alpha gene is positively correlated with expression
1987
Gene organization of DC and DX subregions of the human major histocompatibility complex.
1985
Tumor antigen–specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired
2009
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
2011 StandoutScience
The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition
2016
Both alpha and beta chains of HLA-DC class II histocompatibility antigens display extensive polymorphism in their amino-terminal domains.
1984
Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma
2008 StandoutNobel
Selective anergy of V beta 8+ T cells in human immunodeficiency virus-infected individuals.
1994 StandoutNobel
Polymorphism of human Ia antigens: gene conversion between two DR β loci results in a new HLA-D/DR specificity
1986 Nature
Complete characterization and sequence of an HLA class II DR beta chain cDNA from the DR5 haplotype.
1986
A Pilot Study of CTLA-4 Blockade after Cancer Vaccine Failure in Patients with Advanced Malignancy
2007
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
2016 Standout
Crystallization and X-ray diffraction studies on the histocompatibility antigens HLA-A2 and HLA-A28 from human cell membranes
1985
Combining Radiation and Immunotherapy: A New Systemic Therapy for Solid Tumors?
2014 StandoutNobel
The Mechanism of Anti-CTLA-4 Activity and the Negative Regulation of T-Cell Activation
2008
Epitope Landscape in Breast and Colorectal Cancer
2008 StandoutNobel
Correlation of clinical and immunological data in a metastatic melanoma patient with heterogeneous tumor responses to ipilimumab therapy.
2010 StandoutNobel
Unique potential of 4-1BB agonist antibody to promote durable regression of HPV + tumors when combined with an E6/E7 peptide vaccine
2015 StandoutNobel
Use of pooled DNA samples to detect linkage disequilibrium of polymorphic restriction fragments and human disease: studies of the HLA class II loci.
1985
Linkage map of three HLA-DR beta-chain genes: evidence for a recent duplication event.
1985
The future of immune checkpoint therapy
2015 StandoutScienceNobel
Recognition of Self Antigens by Skin-Derived T Cells with Invariant γδ Antigen Receptors
1991 StandoutScienceNobel
B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome
2007 StandoutNobel
Precision glycocalyx editing as a strategy for cancer immunotherapy
2016 StandoutNobel
Autoimmunity in a Phase I Trial of a Fully Human Anti-Cytotoxic T-Lymphocyte Antigen-4 Monoclonal Antibody With Multiple Melanoma Peptides and Montanide ISA 51 for Patients With Resected Stages III and IV Melanoma
2004
Reactive Oxygen Species (ROS)-Based Nanomedicine
2019 Standout
Ipilimumab Plus Sargramostim vs Ipilimumab Alone for Treatment of Metastatic Melanoma
2014
Antitumor Activity in Melanoma and Anti-Self Responses in a Phase I Trial With the Anti-Cytotoxic T Lymphocyte–Associated Antigen 4 Monoclonal Antibody CP-675,206
2005
Anti-CTLA-4 therapy results in higher CD4 + ICOS hi T cell frequency and IFN-γ levels in both nonmalignant and malignant prostate tissues
2009
cDNA cloning of the bovine low density lipoprotein receptor: feedback regulation of a receptor mRNA.
1983 StandoutNobel
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
2010 StandoutNobel
Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future
2015
Purification of low-abundance messenger RNAs from rat liver by polysome immunoadsorption.
1982
CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit
2008 StandoutNobel
Immunotherapy: Bewitched, Bothered, and Bewildered No More
2004 StandoutScienceNobel
HLA and Disease 1982 ‐ A Survey
1983
Single dose of anti–CTLA-4 enhances CD8 + T-cell memory formation, function, and maintenance
2010 StandoutNobel
Genetic control of diabetes and insulitis in the nonobese diabetic (NOD) mouse.
1987
Phase I/II Study of Ipilimumab for Patients With Metastatic Melanoma
2008
Polymorphism of human Ia antigens generated by reciprocal intergenic exchange between two DR β loci
1986 Nature
Molecular diversity of HLA-DR4 haplotypes.
1986
Sequence analysis and structure-function correlations of murine q, k, u, s, and f haplotype I-A beta cDNA clones.
1986
IFN-α Directly Promotes Programmed Cell Death-1 Transcription and Limits the Duration of T Cell-Mediated Immunity
2011 StandoutNobel
The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: patient cases.
2008
Identification of a polymorphic variant associated with HLA-DQw3 and characterized by specific restriction sites within the DQ beta-chain gene.
1985
Up-Regulation of PD-L1, IDO, and T regs in the Melanoma Tumor Microenvironment Is Driven by CD8 + T Cells
2013 Standout
A Pilot Trial of CTLA-4 Blockade with Human Anti-CTLA-4 in Patients with Hormone-Refractory Prostate Cancer
2007 StandoutNobel
OX40 engagement depletes intratumoral Tregs via activating FcγRs, leading to antitumor efficacy
2014
Clinical Significance of Programmed Death-1 Ligand-1 and Programmed Death-1 Ligand-2 Expression in Human Esophageal Cancer
2005
The scanning model for translation: an update.
1989 Standout
Immune Therapy for Cancer
2008
Three-dimensional structure of beta 2-microglobulin.
1985
Structural organization of the DR subregion of the human major histocompatibility complex.
1985
Immune Checkpoint Blockade in Cancer Therapy
2015 Standout
Cancer immunotherapy using checkpoint blockade
2018 StandoutScience
Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4
2013 StandoutNobel
Correction of the genetic defect in hepatocytes from the Watanabe heritable hyperlipidemic rabbit.
1988
Cutting Edge: CTLA-4 on Effector T Cells Inhibits In Trans
2012 StandoutNobel
Mitochondrial activation chemicals synergize with surface receptor PD-1 blockade for T cell-dependent antitumor activity
2017 StandoutNobel
PD-1 and Its Ligands in Tolerance and Immunity
2008 Standout
DO beta: a new beta chain gene in HLA-D with a distinct regulation of expression.
1985
Cutting Edge: Cell-Extrinsic Immune Regulation by CTLA-4 Expressed on Conventional T Cells
2012
Dual Roles for Immunity in Gastrointestinal Cancers
2010
Nucleotide sequence of an HLA-DQ alpha chain derived from a DRw9 cell line: genetic and evolutionary implications.
1985
Cloning and sequence analysis of the human major histocompatibility complex gene DC-3 beta.
1984
Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti–CTLA-4 antibody
2018 StandoutNobel
Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients
2015
Tumor immune profiling predicts response to anti–PD-1 therapy in human melanoma
2016
Works of Alan J. Korman being referenced
Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies
2009 StandoutNobel
Anti–Programmed Death-1 Synergizes with Granulocyte Macrophage Colony-Stimulating Factor–Secreting Tumor Cell Immunotherapy Providing Therapeutic Benefit to Mice with Established Tumors
2009
Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells
2013
Efficacy of anti-CTLA-4 antibody in the SA1N tumor model when combined with dexamethasone
2007
Activity of Anti-PD-1 in Murine Tumor Models: Role of “Host” PD-L1 and Synergistic Effect of Anti-PD-1 and Anti-CTLA-4 (48.37)
2007
HLA‐DR Antigens: Structure, Separation of Subpopulations, Gene Cloning and Function
1982
Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
2010 Standout
Enhanced protein production by engineered zinc finger proteins
2006
PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+CD25Hi regulatory T cells
2009
Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs
2007
Principles and use of anti-CTLA4 antibody in human cancer immunotherapy
2006 StandoutNobel
Enhanced Tumor Eradication by Combining CTLA-4 or PD-1 Blockade With CpG Therapy
2010
Evolving synergistic combinations of targeted immunotherapies to combat cancer
2015
Checkpoint Blockade in Cancer Immunotherapy
2006 StandoutNobel
FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis
2015
Development of Ipilimumab: Contribution to a New Paradigm for Cancer Immunotherapy
2010
A Randomized, Double-Blind, Placebo-Controlled Assessment of BMS-936558, a Fully Human Monoclonal Antibody to Programmed Death-1 (PD-1), in Patients with Chronic Hepatitis C Virus Infection
2013
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma
2013 StandoutNobel
Expression of HLA-DR Antigen in Human Class II Mutant B-Cell Lines by Double Infection with Retrovirus Vectors
1987
cDNA clones for the heavy chain of HLA-DR antigens obtained after immunopurification of polysomes by monoclonal antibody.
1982
Peripheral and tumor immune correlates in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab.
2013
Immune interferon activates multiple class II major histocompatibility complex genes and the associated invariant chain gene in human endothelial cells and dermal fibroblasts.
1984
Expression of HLA-DR antigen in human class II mutant B-cell lines by double infection with retrovirus vectors.
1987
Phase II experience with MDX-1106 (Ono-4538), an anti-PD-1 monoclonal antibody, in patients with selected refractory or relapsed malignancies
2009
Tumor immunotherapy: preclinical and clinical activity of anti-CTLA4 antibodies.
2005
Anti-PD-1 (BMS-936558, MDX-1106) in patients with advanced solid tumors: Clinical activity, safety, and a potential biomarker for response.
2012
The mouse mammary tumour virus long terminal repeat encodes a type II transmembrane glycoprotein.
1992
Expression of human class II major histocompatibility complex antigens using retrovirus vectors.
1987
The amino acid sequence and gene organization of the heavy chain of the HLA-DR antigen: homology to immunoglobulins.
1982
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients
2008 StandoutNobel
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients
2003 StandoutNobel
Activity and Safety of CTLA-4 Blockade Combined with Vaccines in Cynomolgus Macaques
2003
Predominant variable region gene usage by gamma/delta T cell receptor-bearing cells in the adult thymus.
1988
High-Programmed Death-1 Levels on Hepatitis C Virus-Specific T Cells during Acute Infection Are Associated with Viral Persistence and Require Preservation of Cognate Antigen during Chronic Infection
2008
The class II molecules of the human and murine major histocompatibility complex
1984
TIGIT and PD-1 impair tumor antigen–specific CD8+ T cells in melanoma patients
2015
Cutting Edge: Accelerated Autoimmune Diabetes in the Absence of LAG-3
2011
cDNA clone for the heavy chain of the human B cell alloantigen DC1: strong sequence homology to the HLA-DR heavy chain.
1982
Organization of the transcriptional unit of a human class II histocompatibility antigen: HLA-DR heavy chain
1983
Genetic Complexity and Expression of Human Class II Histocompatibility Antigens
1985